{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:32:44Z","timestamp":1778013164940,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health System Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jvacx.2024.100538","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:11:03Z","timestamp":1722175863000},"page":"100538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and antibody responses of Omicron BA.4\/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-6353","authenticated-orcid":false,"given":"Sitthichai","family":"Kanokudom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jira","family":"Chansaenroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-6470","authenticated-orcid":false,"given":"Nungruthai","family":"Suntronwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakkhana","family":"Wongsrisang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratchadawan","family":"Aeemjinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeyaporn","family":"Vichaiwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaksaporn","family":"Thatsanathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warangkana","family":"Chantima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-2539","authenticated-orcid":false,"given":"Pattarakul","family":"Pakchotanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-9994","authenticated-orcid":false,"given":"Thaneeya","family":"Duangchinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natthinee","family":"Sudhinaraset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sittisak","family":"Honsawek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-6807","authenticated-orcid":false,"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100538_b0005","unstructured":"World Health Organization. Number of COVID-19 cases reported to WHO (cumulative total), https:\/\/covid19.who.int; 2023 [accessed 17 December 2023]."},{"key":"10.1016\/j.jvacx.2024.100538_b0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/v14040653","article-title":"SARS-CoV-2: evolution and emergence of new viral variants","volume":"14","author":"Flores-Vega","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2024.100538_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0020","doi-asserted-by":"crossref","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2024.100538_b0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2024.100538_b0030","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/jmv.27516","article-title":"Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa","volume":"94","author":"Wang","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.jvacx.2024.100538_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112443","article-title":"Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants","volume":"42","author":"Qu","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jvacx.2024.100538_b0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jvacx.2024.100538_b0050","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/infdis\/jiac460","article-title":"Impact of vaccination, prior infection, and therapy on Omicron infection and mortality","volume":"227","author":"Wang","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100538_b0055","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine rffectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0060","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of bivalent boosters against severe Omicron infection","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0065","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","article-title":"Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection - increasing community access to testing program, United States, September-November 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jvacx.2024.100538_b0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster","volume":"388","author":"Davis-Gardner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41541-023-00779-8","article-title":"BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer","volume":"8","author":"Valanparambil","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jvacx.2024.100538_b0080","doi-asserted-by":"crossref","first-page":"e075286","DOI":"10.1136\/bmj-2022-075286","article-title":"Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged \u226550 years in Nordic countries: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jvacx.2024.100538_b0085","doi-asserted-by":"crossref","unstructured":"Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early Estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB\/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep 2023;72(5):119-24. Doi: 10.15585\/mmwr.mm7205e1.","DOI":"10.15585\/mmwr.mm7205e1"},{"key":"10.1016\/j.jvacx.2024.100538_b0090","doi-asserted-by":"crossref","first-page":"2300087","DOI":"10.2807\/1560-7917.ES.2023.28.7.2300087","article-title":"Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022","volume":"28","author":"Huiberts","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jvacx.2024.100538_b0095","doi-asserted-by":"crossref","first-page":"taad106","DOI":"10.1093\/jtm\/taad106","article-title":"Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections","volume":"30","author":"Chemaitelly","year":"2023","journal-title":"J Travel Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0100","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jvacx.2024.100538_b0105","unstructured":"The Global Initiative on Sharing All Influenza Data (GISAID). Tracking of hCoV-19 variants, https:\/\/gisaid.org\/hcov19-variants\/; 2023 [accessed 08 November 2023]."},{"key":"10.1016\/j.jvacx.2024.100538_b0110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/vaccines11030570","article-title":"The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: safety and immunogenicity to Omicron BA.4\/BA.5","volume":"11","author":"Kanokudom","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100538_b0115","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2024.100538_b0120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100538_b0125","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0130","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1038\/s41598-023-42754-2","article-title":"Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023","volume":"13","author":"Chansaenroj","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jvacx.2024.100538_b0135","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3390\/vaccines11111693","article-title":"Real-world study: hybrid immunity against SARS-CoV-2 influences the antibody levels and persistency lasting more than one year","volume":"11","author":"Kanokudom","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100538_b0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jvacx.2024.100538_b0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to Omicron BA.4-BA.5 bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0155","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0160","unstructured":"WHO\u2019s Strategic Advisory Group on Immunization (SAGE). Increasing COVID-19 vaccination uptake; an update on messaging, delivery strategies and policy recommendation (1 December 2023), https:\/\/www.who.int\/publications\/m\/item\/increasing-covid-19-vaccination-uptake; 2023 [accessed on 7 December 2023]."},{"key":"10.1016\/j.jvacx.2024.100538_b0165","article-title":"Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: community-based, matched cohort study. Open Forum","volume":"9","author":"Ayoubkhani","year":"2022","journal-title":"Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100538_b0170","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","article-title":"Long COVID after breakthrough SARS-CoV-2 infection","volume":"28","author":"Al-Aly","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jvacx.2024.100538_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101624","article-title":"Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review","volume":"53","author":"Notarte","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:29:05Z","timestamp":1729020545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"alternative-id":["S2590136224001116"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100538","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and antibody responses of Omicron BA.4\/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100538"}}